palmitoylethanolamide.com.au
HomeResearchChiara 2024

Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells

Chiara Camoglio, Jihane Balla, Paola Fadda, Simona Dedoni. Molecules. 2024 Apr 2;29(7):1592.

Laboratory studyHumansWith interferon beta (co-exposure); oleoylethanolamide tested in parallel

This study tested palmitoylethanolamide together with interferon beta (co-exposure); oleoylethanolamide tested in parallel. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Laboratory study
Subjects
Human SH-SY5Y neuroblastoma cell line
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Cell viability, proliferation, apoptosis markers (cleaved caspase 3, PARP, survivin, IKB-alpha), JAK-STAT and PKR signalling, p38 MAP kinase and PD-L1 expression.

What the authors reported

The study found:

  • Adding either OEA or PEA to interferon beta increased apoptotic cell death, with more cleaved caspase 3 and PARP and less survivin and IKB-alpha.
  • Neither lipid changed interferon signalling through JAK-STAT or PKR.
  • Both raised p38 phosphorylation and PD-L1 expression.
  • Blocking or silencing PPAR-alpha lowered PD-L1 and cleaved PARP.

Limits of this study

A cancer cell line study; it cannot show effect in people. No doses or exposure times are given in the abstract. The authors declare no conflict of interest.

Source

PubMed 38611871 · doi:10.3390/molecules29071592

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.